Clinical Trials Browser

OTHER × Uterine Cervical Neoplasms × Nivolumab × Clear all

NCT07223424 2026-04-16

PSI-Immune

Phase 2 Recruiting

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT03298893 2025-09-19

NiCOL

Phase 1/2 Completed

Uterine Cervical Neoplasms

NCT03508570 2025-05-22

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Phase 1 Completed

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT03527264 2025-04-04

BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer

Phase 2 Terminated

4 enrolled 11 charts

Uterine Cervical Neoplasms

NCT04256213 2024-12-12

COLIBRI

Phase NA Completed

Uterine Cervical Neoplasms

NCT05492123 2024-01-05

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT05504642 2023-04-18

CERAD-IMMUNE

Phase 2 Withdrawn

Uterine Cervical Neoplasms, Lymphatic Metastasis